XML 58 R50.htm IDEA: XBRL DOCUMENT
v3.25.3

License and Collaboration Agreements - Additional Information (Detail) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2020 USD ($) | Sep. 30, 2025 USD ($) License | Aug. 31, 2025 USD ($) | Jan. 31, 2024 USD ($) | Oct. 31, 2023 USD ($) | Apr. 30, 2023 USD ($) | Jan. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Aug. 31, 2021 USD ($) | Jun. 30, 2021 Program | Sep. 30, 2025 USD ($) License | Sep. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) License | Sep. 30, 2024 USD ($) | Dec. 31, 2023 USD ($) | Jul. 01, 2025 USD ($) Price | Jul. 31, 2021 USD ($) | Jan. 31, 2021 USD ($) | Oct. 31, 2020 USD ($)
SYFOVRE [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payments |  |  |  | $ 3,000,000 | $ 2,000,000 | $ 2,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense |  |  |  |  |  |  |  |  |  |  |  | $ 4,900,000 | $ 4,900,000 | $ 14,100,000 | $ 14,400,000 |  |  |  |  |
Regulatory milestone incurred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |
EMPAVELI and Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense |  |  |  |  |  |  |  |  |  |  |  | 2,000,000 | 1,800,000 | 5,300,000 | 5,000,000 |  |  |  |  |
Swedish Orphan Biovitrum AB (Publ) [Member] | Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Revenue |  |  |  |  |  |  |  |  |  |  |  | 600,000 | 5,000,000 | 12,600,000 | 13,900,000 |  |  |  |  |
Royalty Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 275,000,000 |  |  |
Aggregate amount agreed to be received upon European Medicines Agency approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of regulatory development milestone |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement received |  |  |  |  |  |  |  |  |  |  |  |  |  | 65,000,000 |  |  |  |  |  |
Waived Payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |
Royalties entitled to receive after first commercial sale of applicable licensed product period |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |
Caps intial purchase price | Price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.45 |  |  |
Percentage of royalty payment obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90.00% |  |  |
Percentage of royalty payment obligation reverted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |
Contract research and development expense |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | $ 0 | 0 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  | 5,200,000 | $ 15,300,000 | 17,200,000 | $ 36,200,000 |  |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 915,000,000
Development cost reimbursement |  |  |  |  |  |  |  |  |  |  |  |  |  | 80,000,000 |  |  |  |  |  |
University of Pennsylvania [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development milestone achievement |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Additional payment upon for sublicense fee related to collaboration agreement |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |
University of Pennsylvania [Member] | EMPAVELI and Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
University of Pennsylvania [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  | $ 3,200,000 |  |  |  |  |  |  |  |  |  | $ 3,200,000 |  | 3,200,000 |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |
2010 License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of licensed products | License |  | 2 |  |  |  |  |  |  |  |  |  | 2 |  | 2 |  |  |  |  |  |
2010 License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  | $ 1,700,000 |  |  |  |  |  |  |  |  |  | $ 1,700,000 |  | $ 1,700,000 |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |
Sobi Agreement and Another Licensing Transaction [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fee owed |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |
Research Collaboration Agreement [Member] | Beam Therapeutics Incorporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement term |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Number of research programs | Program |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |
Up-front non-refundable payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |
Up-front payment on first anniversary of agreement on June 30, 2022 |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement maximum extendable term |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |
Neonatal Fc Receptor [Member[ | Beam Therapeutics Incorporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 3,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Neonatal Fc Receptor [Member[ | Beam Therapeutics Incorporation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of regulatory development milestone |  |  | $ 168,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  | $ 215,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional payment upon for sublicense fee related to collaboration agreement. + References No definition available. + Details
Name: | apls_AdditionalPaymentUponForSublicenseFeeRelatedToCollaborationAgreement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate amount agreed to be received upon agency approval. + References No definition available. + Details
Name: | apls_AggregateAmountAgreedToBeReceivedUponAgencyApproval
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events. + References No definition available. + Details
Name: | apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryDevelopmentAndCommercialMilestoneEvents
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative arrangement, maximum extendable term of agreement. + References No definition available. + Details
Name: | apls_CollaborativeArrangementMaximumExtendableTermOfAgreement
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, number of research programs. + References No definition available. + Details
Name: | apls_CollaborativeArrangementNumberOfResearchPrograms
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, term of agreement. + References No definition available. + Details
Name: | apls_CollaborativeArrangementTermOfAgreement
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, up-front payment in next twelve months. + References No definition available. + Details
Name: | apls_CollaborativeArrangementUpFrontPaymentInNextTwelveMonths
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement upfront non-refundable amount payable. + References No definition available. + Details
Name: | apls_CollaborativeArrangementUpfrontNonRefundableAmountPayable
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contra research and development expense. + References No definition available. + Details
Name: | apls_ContraResearchAndDevelopmentExpense
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development cost reimbursement. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development cost reimbursement received. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursementReceived
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestone achievement. + References No definition available. + Details
Name: | apls_DevelopmentMilestoneAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment received for achievement of regulatory development milestone. + References No definition available. + Details
Name: | apls_MilestonePaymentReceivedForAchievementOfRegulatoryDevelopmentMilestone
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products. + References No definition available. + Details
Name: | apls_NumberOfLicensedProducts
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of royalty payment obligation. + References No definition available. + Details
Name: | apls_PercentageOfRoyaltyPaymentObligation
Namespace Prefix: | apls_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of royalty payment obligation reverted. + References No definition available. + Details
Name: | apls_PercentageOfRoyaltyPaymentObligationReverted
Namespace Prefix: | apls_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Performance obligation caps intial purchase price. + References No definition available. + Details
Name: | apls_PerformanceObligationCapsIntialPurchasePrice
Namespace Prefix: | apls_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Regulatory milestone incurred based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestoneIncurredBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory milestone payments based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestonePaymentsBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties entitled to receive after first commercial sale of applicable licensed product period. + References No definition available. + Details
Name: | apls_RoyaltiesEntitledToReceiveAfterFirstCommercialSaleOfApplicableLicensedProductPeriod
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty revenue. + References No definition available. + Details
Name: | apls_RoyaltyRevenue
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales milestone payments based on achievement of annual sales milestones. + References No definition available. + Details
Name: | apls_SalesMilestonePaymentsBasedOnAchievementOfAnnualSalesMilestones
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sublicense fee owed. + References No definition available. + Details
Name: | apls_SublicenseFeeOwed
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | apls_UpfrontPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment to be received. + References No definition available. + Details
Name: | apls_UpfrontPaymentToBeReceived
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Waived payment. + References No definition available. + Details
Name: | apls_WaivedPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=apls_SyfovreMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_EmpaveliAndAspaveliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=apls_SwedishOrphanBiovitrumABPublMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_AspaveliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_RoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_UniversityOfPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_TwoThousandTenLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_SobiAgreementAndAnotherLicensingTransactionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_ResearchCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=apls_BeamTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_NeonatalFcReceptorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |